GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals has submitted copies of newspaper advertisements (Economic Times, Business Standard, and Maharashtra Times) publishing its unaudited financial results for the quarter ended 30 June 2025, as required under Regulation 47 of the SEBI Listing Rules. Standalone revenue from operations came in at ₹804.83 crore, marginally lower than ₹811 crore in the same quarter last year but down from ₹966.08 crore in the preceding quarter (Q4 FY25). Net profit after tax stood at ₹204.70 crore, up about 12.7% year-on-year from ₹181.65 crore in Q1 FY25, though lower sequentially. Basic and diluted EPS for the quarter was ₹12.08 versus ₹10.72 a year ago, reflecting margin improvement. Consolidated revenue was ₹805.17 crore with net profit of ₹205.01 crore and EPS of ₹12.10. The results were approved by the Board on 1 August 2025.
Marginal YoY revenue softness but healthy double-digit profit and EPS growth signal margin expansion, which is mildly positive for shareholders. The filing itself is a routine regulatory disclosure and is unlikely to move the stock on its own.